Sweet sorghum planting effects on stalk yield and sugar quality in semi-arid tropical environment

Not AvailableSweet sorghum [Sorghum bicolor (L.) Moench] has potential as a bioenergy crop for producing food, fiber, and fermentable sugar. Unlike dryland grain sorghum, little information is available on the influence of staggered planting and genotypes, especially in semiarid tropical environments. The objectives of the present study were (i) to quantify the effects of planting time and genotype on stalk and biomass yields, juice sugar quality, and (ii) to identify the most productive genotypes and planting windows for sustainable feedstock supply. Four commercial sweet sorghum genotypes (SSV84, SSV74, CSV19SS, and CSH22SS) were planted on five planting dates (1 June, 16 June, 1 July, 16 July, and 1 August) during the rainy (June–October) season of 2008 and 2009 in Hyderabad (17°27´ N, 78°28´ E), India. Planting in early and mid-June produced significantly (P ≤ 0.05) higher fresh stalk yield and grain yield than later planting dates. Commercial hybrid CSH22SS produced significantly more stalk, grain, sugar, and ethanol yield over genotypes SSV84 or SSV74. Based on the stalk yield, juice sugar quality, sugar, and ethanol yields, the optimum planting dates for sweet sorghum in semiarid tropical climate is early June to early July. Planting sweet sorghum during this time allows more feedstock to be harvested and hence extends the period for sugar mill operation by about 1 mo, that is, from the first to the last week of October.Not Availabl

Sustained progress, but no room for complacency: Results of 2015 HIV estimations in India

Background & objectives: Evidence-based planning has been the cornerstone of India's response to HIV/AIDS. Here we describe the process, method and tools used for generating the 2015 HIV estimates and provide a summary of the main results. Methods: Spectrum software supported by the UNAIDS was used to produce HIV estimates for India as a whole and its States/Union Territories. This tool takes into consideration the size and HIV prevalence of defined population groups and programme data to estimate HIV prevalence, incidence and mortality over time as well as treatment needs. Results: India's national adult prevalence of HIV was 0.26 per cent in 2015. Of the 2.1 million people living with HIV/AIDS, the largest numbers were in Andhra Pradesh, Maharashtra and Karnataka. New HIV infections were an estimated 86,000 in 2015, reflecting a decline by around 32 per cent from 2007. The declining trend in incidence was mirrored in most States, though an increasing trend was detected in Assam, Chandigarh, Chhattisgarh, Gujarat, Sikkim, Tripura and Uttar Pradesh. AIDS-related deaths were estimated to be 67,600 in 2015, reflecting a 54 per cent decline from 2007. There were variations in the rate and trend of decline across India for this indicator also. Interpretation & conclusions: While key indicators measured through Spectrum modelling confirm success of the National AIDS Control Programme, there is no room for complacency as rising incidence trends in some geographical areas and population pockets remain the cause of concern. Progress achieved so far in responding to HIV/AIDS needs to be sustained to end the HIV epidemic

SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020–January 2021

Background: Earlier serosurveys in India revealed seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) of 0.73% in May–June 2020 and 7.1% in August–September 2020. A third serosurvey was conducted between December 2020 and January 2021 to estimate the seroprevalence of SARS-CoV-2 infection among the general population and healthcare workers (HCWs) in India. Methods: The third serosurvey was conducted in the same 70 districts as the first and second serosurveys. For each district, at least 400 individuals aged ≥10 years from the general population and 100 HCWs from subdistrict-level health facilities were enrolled. Serum samples from the general population were tested for the presence of immunoglobulin G (IgG) antibodies against the nucleocapsid (N) and spike (S1-RBD) proteins of SARS-CoV-2, whereas serum samples from HCWs were tested for anti-S1-RBD. Weighted seroprevalence adjusted for assay characteristics was estimated. Results: Of the 28,598 serum samples from the general population, 4585 (16%) had IgG antibodies against the N protein, 6647 (23.2%) had IgG antibodies against the S1-RBD protein, and 7436 (26%) had IgG antibodies against either the N protein or the S1-RBD protein. Weighted and assay-characteristic-adjusted seroprevalence against either of the antibodies was 24.1% [95% confidence interval (CI) 23.0–25.3%]. Among 7385 HCWs, the seroprevalence of anti-S1-RBD IgG antibodies was 25.6% (95% CI 23.5–27.8%). Conclusions: Nearly one in four individuals aged ≥10 years from the general population as well as HCWs in India had been exposed to SARS-CoV-2 by December 2020